Drug Trial Radar · NCT07742098
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Dec 15, 2028
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- NeuroTrauma Sciences, LLCIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
Conditions
- Acute Ischemic Stroke
Interventions
NTS-521Drug
Intravenous NTS-521
Placebo ControlOther
0.9% saline solution delivered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety AssessmentTime frame: Safety assessments between baseline and Day 30 and Day 90
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.